Mode
Text Size
Log in / Sign up
N/A N=15 Randomized Double-blind Treatment

Effect of Two Toothpastes on Bacteria in Saliva

Oral Health

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Change From Baseline in Area Under the Curve Between 0 and 2 Hours (AUC [0-2] Hours) for Total Viable Counts (TVCs) of Bacteria in Saliva Using Traditional Plating Technique — 8.818; 8.785; 8.845; -0.037 Log10 (cells/ml) — p=0.1787

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Zinc-A toothpaste (Drug); Zinc-B toothpaste (Drug); Mineral water (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Nov 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Area Under the Curve Between 0 and 2 Hours (AUC [0-2] Hours) for Total Viable Counts (TVCs) of Bacteria in Saliva Using Traditional Plating Technique
8.818; 8.785; 8.845; -0.037; -0.348; 0.193 0.1787
SECONDARY
Change From Baseline in AUC (0-2) Hours for the Ratio of Live:Dead Bacteria Using Live-dead Staining Technique
0.758; 0.946; 0.906; -7.612; -10.927; -1.024
SECONDARY
Change From Baseline in log10-transformed Total Viable Bacterial Count Using Traditional Bacterial Plating Technique
-0.364; -0.474; 0.144; -0.030; -0.214; 0.161
SECONDARY
Change From Baseline in Live:Dead Bacteria Ratio in Saliva Using Staining Technique
-4.701; -6.728; -0.049; -4.259; -6.153; -0.820

Summary

This study investigated the ability of two zinc-containing toothpaste formulations (Zinc A and Zinc B) to reduce the level of bacteria in saliva in the two-hour period after their use, compared to the effect of rinsing with water alone.

Eligibility Criteria

Inclusion Criteria

  • Personnel: GSKCH permanent and contract/contingency workers.
  • Consent: Demonstrated understanding of the study and was willing to participate and had received a signed and dated copy of the informed consent form.
  • Compliance: Understood, was willing and able and complied with all study procedures and restrictions.
  • General Health: Good general health
  • Oral Health: Good oral health
  • Salivary Flow Rate: Had a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2milliliter per minute (ml/min); stimulated whole saliva flow rate ≥ 0.8ml/min)

Exclusion Criteria

  • Study personnel: Members of the clinical study staff.
  • Pregnancy: Pregnant Women
  • Breast-feeding: Women who were breast-feeding.
  • Allergy/Intolerance: Had Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Medication: a) Used an antimicrobial mouthwash within 48 hours of the test visit e.g. Listerine, Corsodyl etc. b) had taken, antibiotics within 2 weeks of the test visit.
  • Oral Surgery and Dental Conditions: a)Had an on-going dental treatment b) Had any oral surgery or extraction within 6 weeks of screening c) Symptoms of oral pain or any self-reported oral ulcers or herpetic lesions
  • Clinical Study Participation: a) Participation in a clinical study where they received an investigational drug within 2 weeks of the screening visit b) Previously participated in this study.
  • Substance Abstinence: Participant who were unwilling to abstain from smoking for at least 2 hours prior to treatment visits.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03587428). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search